Adverse Effects of the Oral Anticancer Drug S-1: Lacrimal Passage Impairment and Specific Features of Corneal Epitheliopathy
Ken-ichi Sato*, Shin-ichi Nishimura
Identifiers and Pagination:Year: 2013
First Page: 85
Last Page: 86
Publisher ID: TOOPHTJ-7-85
Article History:Received Date: 4/7/2013
Revision Received Date: 21/11/2013
Acceptance Date: 28/11/2013
Electronic publication date: 30/12/2013
Collection year: 2013
open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
We report the incidence of lacrimal passage impairment and specific features of corneal epitheliopathy as adverse effects of the oral anticancer drug S-1, and examine the relationship between the two pathologies. We conducted a retrospective chart review of 84 patients prescribed the anticancer drug S-1. The incidence of lacrimal passage impairment and corneal epitheliopathy was 8% and 6%, respectively. Three patients experienced both pathologies, demonstrating a moderate probability of both occurring in the same patient (kappa coefficient = 0.46). The findings show that lacrimal passage impairment and specific features of corneal epitheliopathy are likely to occur in the same individual as adverse effects of S-1.